wer kann darüber was sagen.
gruß Grenke
gruß Grenke
Top-News
NNBP Nannotech mit Risiko ??
Beiträge:
3
Zugriffe: 850 / Heute: 1
Zugriffe: 850 / Heute: 1
TAMPA, Fla., Feb 2, 2004 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc.
(OTCPK:NNBP) ("Nanobac" or "The Company") Chairman of the Board, John Stanton,
announces the election of Dr. Jan Egberts and Dr. Stephan Rechtschaffen as
independent directors of the Company.
"In the election of these directors, the company has sought to bring a diverse
group of executives to the leadership of the company," said Mr. Stanton. "Both
of these directors bring unique corporate and medical experiences that will be
integral in guiding the company in the successful execution of its business
plan."
Dr. Jan Egberts received his medical degree from Erasmus University Medical
School, Rottendam, the Netherlands in 1985, with medical studies at John Hopkins
and Harvard medical schools. He received his MBA from Stanford Graduate School
of Business in 1989.
For the past three years he has served as Chairman and Managing Director of
Molnlycke Healthcare, Inc. in Newtown, PA.
Prior to Molnlycke, Dr. Egberts served as Vice President, Business and Market
Development world wide for Johnson & Johnson, New Brunswick, NJ. He was a member
of the Global Management Board of $1.3 billion Johnson & Johnson medical
franchise with seven divisions. He was responsible for licensing/acquisitions,
equity investment and patent management.
Prior to Johnson & Johnson, Dr. Egberts was a Senior Marketing Director with
Merck & Company in West Point, PA; Partner, Egberts & Company, Amsterdam;
Engagement Manager, McKinsey & Company in New York, Dusseldorf, London and
Amsterdam; Project Manager, Cancer Biotechnology Research and Development
Organon/Bionetics Research, Inc.
Dr. Stephan Rechtschaffen received his medical degree in 1973 from New York
Medical College in New York City. His residency was at Harkness Community
Hospital in San Francisco. He co-founded Omega Institute in 1977 and is the CEO
and Chair of the Board. He was the developer and director of Foxhollow Wellness
Spa in Lenox, MA from 1987 - 1989, and director of the Rhinebeck Health Center
in Rhinebeck, NY, from 1983 - 1989.
Dr. Rechtschaffen is a nationally recognized holistic physician who lectures on
health, wellness, nutrition, longevity and time. He has organized symposia and
educational programs throughout the country.
Dr. Rechtschaffen is the author of: TimeShifting; Creating More Time to Enjoy
Your Life, 1996, published in the United States by Doubleday, and in England,
Europe, Japan and Australia by Random House. He is co-author of Vitality and
Wellness, 1999, published by Dell.
Dr. Rechtschaffen has presented these concepts in TimeShifting, Health and
Wellness, and in Organizational Management workshops at many corporations:
Citibank, Avon, Aveda, ConEdison, IBM, Dana Farber Cancer Institute, Kaiser
Permanente, Mercedes-Benz, Natural Health Business Strategies, Preventative
Medicine Research, Salon Systems and Young Presidents Organization, and others.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A. For
more information, please visit our website at www.nanobaclabs.com or contact us
at info@nanobaclabs.com.
Investors are cautioned that certain statements contained in this document as
well as some statements in periodic press releases and some oral statements of
Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within
the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act").
Forward-Looking statements include statements which are predictive in nature,
which depend upon or refer to future events or conditions, which include words
such as "believes," "anticipates," "intends," "plans," "expects," and similar
expressions. In addition, any statements concerning future financial performance
(including future revenues, earnings or growth rates), ongoing business
strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc.
actions, which may be provided by management, are also forward-looking
statements as defined by the Act. Forward-Looking statements involve known and
unknown risks, uncertainties, and other factors which might cause the actual
results, performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied by such
forward-looking statements and to vary significantly from reporting period to
reporting period. Although management believes that the assumptions will, in
fact, prove to be correct or that actual future results will not be different
from the expectations expressed in this report, these statements are not
guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no
specific intention to update these statements.
SOURCE: Nanobac Pharmaceuticals, Inc.
CONTACT: Nanobac Pharmaceuticals, Inc., Tampa
Alex Edwards, 813/264-2241
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.
(OTCPK:NNBP) ("Nanobac" or "The Company") Chairman of the Board, John Stanton,
announces the election of Dr. Jan Egberts and Dr. Stephan Rechtschaffen as
independent directors of the Company.
"In the election of these directors, the company has sought to bring a diverse
group of executives to the leadership of the company," said Mr. Stanton. "Both
of these directors bring unique corporate and medical experiences that will be
integral in guiding the company in the successful execution of its business
plan."
Dr. Jan Egberts received his medical degree from Erasmus University Medical
School, Rottendam, the Netherlands in 1985, with medical studies at John Hopkins
and Harvard medical schools. He received his MBA from Stanford Graduate School
of Business in 1989.
For the past three years he has served as Chairman and Managing Director of
Molnlycke Healthcare, Inc. in Newtown, PA.
Prior to Molnlycke, Dr. Egberts served as Vice President, Business and Market
Development world wide for Johnson & Johnson, New Brunswick, NJ. He was a member
of the Global Management Board of $1.3 billion Johnson & Johnson medical
franchise with seven divisions. He was responsible for licensing/acquisitions,
equity investment and patent management.
Prior to Johnson & Johnson, Dr. Egberts was a Senior Marketing Director with
Merck & Company in West Point, PA; Partner, Egberts & Company, Amsterdam;
Engagement Manager, McKinsey & Company in New York, Dusseldorf, London and
Amsterdam; Project Manager, Cancer Biotechnology Research and Development
Organon/Bionetics Research, Inc.
Dr. Stephan Rechtschaffen received his medical degree in 1973 from New York
Medical College in New York City. His residency was at Harkness Community
Hospital in San Francisco. He co-founded Omega Institute in 1977 and is the CEO
and Chair of the Board. He was the developer and director of Foxhollow Wellness
Spa in Lenox, MA from 1987 - 1989, and director of the Rhinebeck Health Center
in Rhinebeck, NY, from 1983 - 1989.
Dr. Rechtschaffen is a nationally recognized holistic physician who lectures on
health, wellness, nutrition, longevity and time. He has organized symposia and
educational programs throughout the country.
Dr. Rechtschaffen is the author of: TimeShifting; Creating More Time to Enjoy
Your Life, 1996, published in the United States by Doubleday, and in England,
Europe, Japan and Australia by Random House. He is co-author of Vitality and
Wellness, 1999, published by Dell.
Dr. Rechtschaffen has presented these concepts in TimeShifting, Health and
Wellness, and in Organizational Management workshops at many corporations:
Citibank, Avon, Aveda, ConEdison, IBM, Dana Farber Cancer Institute, Kaiser
Permanente, Mercedes-Benz, Natural Health Business Strategies, Preventative
Medicine Research, Salon Systems and Young Presidents Organization, and others.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A. For
more information, please visit our website at www.nanobaclabs.com or contact us
at info@nanobaclabs.com.
Investors are cautioned that certain statements contained in this document as
well as some statements in periodic press releases and some oral statements of
Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within
the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act").
Forward-Looking statements include statements which are predictive in nature,
which depend upon or refer to future events or conditions, which include words
such as "believes," "anticipates," "intends," "plans," "expects," and similar
expressions. In addition, any statements concerning future financial performance
(including future revenues, earnings or growth rates), ongoing business
strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc.
actions, which may be provided by management, are also forward-looking
statements as defined by the Act. Forward-Looking statements involve known and
unknown risks, uncertainties, and other factors which might cause the actual
results, performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied by such
forward-looking statements and to vary significantly from reporting period to
reporting period. Although management believes that the assumptions will, in
fact, prove to be correct or that actual future results will not be different
from the expectations expressed in this report, these statements are not
guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no
specific intention to update these statements.
SOURCE: Nanobac Pharmaceuticals, Inc.
CONTACT: Nanobac Pharmaceuticals, Inc., Tampa
Alex Edwards, 813/264-2241
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.
Es gibt keine neuen Beiträge.
